Optimind Pharma Corp. is a Canadian pharmaceutical company focused on psychedelic therapies for mental health conditions. While it boasts a high gross margin of 100%, its negative EBITDA and net margins of -40.1% raise concerns about profitability. Additionally, a current ratio of 0.56 indicates potential liquidity issues, as the company may struggle to meet short-term obligations. The significant drop in stock price today (-50.00%) further highlights volatility and investor uncertainty despite its innovative approach in the healthcare sector.
Loading financial metrics...
Company posted a loss of $-31K over the last year, representing 26.6% of revenue.
Gross profit margin decreased from 75.2% to 67.7% compared to last year.
Operating margin expanded by 346.4pp, demonstrating strong operational leverage.
Exceptional gross margin of 67.7% indicates strong pricing power and competitive moat.
Excellent operating cash flow margin of 39.1% indicates high-quality earnings.
Strong balance sheet with net cash position provides cushion for growth investments.
Strong free cash flow margin of 39.1% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q2 (August 31, 2025)